So as of May 2026, the Bridge is the only confirmed pathway for Medicare to cover GLP-1s for weight loss
It shares 94% sequence homology with human GLP-1 but has been structurally modified to resist rapid enzymatic breakdown, giving it a significantly extended half-life compared to native GLP-1
That said, there are biologically plausible indirect pathways by which semaglutide treatmentespecially when accompanied by rapid appetite suppression, gastrointestinal adverse effects, and clinically meaningful weight losscould unmask or exacerbate pre-existing vaginal symptoms (for example, genitourinary syndrome of menopause) or contribute to discomfort through dehydration, altered sex steroid milieu, or pelvic soft-tissue volume changes
[DOI] [PubMed] [Google Scholar] 26.Hansen KB, Svendstrup M, Lund A, Knop FK, Vilsbll T, Vestergaard H
[DOI] [Google Scholar] 68.Ngabea M.A., Dimeji I.Y